Cayston Patent Expiration

Cayston is a drug owned by Gilead Sciences Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 20, 2021. Details of Cayston's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399496 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Dec, 2021

(2 years ago)

Expired
US7208141 Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections
Dec, 2021

(2 years ago)

Expired
US7214364 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Dec, 2021

(2 years ago)

Expired
US7427633 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Dec, 2021

(2 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cayston's patents.

Given below is the list of recent legal activities going on the following patents of Cayston.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 23 Mar, 2020 US7427633
Payment of Maintenance Fee, 12th Year, Large Entity 08 Nov, 2018 US7214364
Payment of Maintenance Fee, 12th Year, Large Entity 24 Oct, 2018 US7208141
Notice of Final Determination- Ineligible 31 Mar, 2015 US7208141
Notice of Final Determination- Ineligible 31 Mar, 2015 US7214364
Notice of Final Determination- Ineligible 31 Mar, 2015 US7427633
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 21 Jun, 2013 US7214364
Letter from FDA or Dept of Agriculture re PTE application 05 Mar, 2012 US7214364
Letter from FDA or Dept of Agriculture re PTE application 05 Mar, 2012 US7208141
Mail-Record Petition Decision of Granted Related to Inventor in Patent 29 Dec, 2011 US7427633


FDA has granted several exclusivities to Cayston. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Cayston, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Cayston.

Exclusivity Information

Cayston holds 1 exclusivities. All of its exclusivities have expired in 2017. Details of Cayston's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Feb 22, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Cayston is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cayston's family patents as well as insights into ongoing legal events on those patents.

Cayston's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Cayston's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 20, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Cayston Generics:

Aztreonam is the generic name for the brand Cayston. 3 different companies have already filed for the generic of Cayston, with Fresenius Kabi Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cayston's generic





About Cayston

Cayston is a drug owned by Gilead Sciences Inc. It is used for improving respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston uses Aztreonam as an active ingredient. Cayston was launched by Gilead in 2010.

Approval Date:

Cayston was approved by FDA for market use on 22 February, 2010.

Active Ingredient:

Cayston uses Aztreonam as the active ingredient. Check out other Drugs and Companies using Aztreonam ingredient

Treatment:

Cayston is used for improving respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.

Dosage:

Cayston is available in for solution form for inhalation use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
75MG/VIAL FOR SOLUTION Prescription INHALATION